- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00151684
Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men
Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men: a Dose Response Study, Part II
The purpose of this study is to explore diazoxide efficacy in treatment of obese men and assessment of maximal insulin suppression in obese men without hyperglycaemia.
Obesity is associated with markedly elevated plasma insulin levels throughout the day. The concept is that obese subjects predominantly develop lean tissue resistance against the glucoregulatory actions of insulin, but remain relatively sensitive to the lipogenic and antilipolytic effects of insulin in adipose tissue. According to this theory, suppression of hyperinsulinism by diazoxide, a well known inhibitor of glucose stimulated insulin secretion, might be useful to treat obesity because it will help to reverse the process of lipid storage.
Study Overview
Detailed Description
The purpose of this study is to explore diazoxide efficacy in treatment of obese men and assessment of maximal insulin suppression in obese men without hyperglycaemia.
Study design:
This study is an open-labelled, non-randomized, phase IIa study.
Treatment:
During a 6 month period, the dosage of Diazoxide will be raised gradually until a maximum of 900 mg/day, under control of bloodpressure and glucose levels.
Endpoints, monthly determined:
- body weight
- abdominal circumference
- body composition measured by Dual Energy X-ray Absorptiometry
- glucose tolerance
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Arnhem, Netherlands
- Rijnstate Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- fasting glucose < 7.0 mmol/L
- fasting C-peptide plasma level > 1.0 nmol/L
- HbA1c of 6.0% or lower
- Absence of comorbidity
- Absence of medication use
Exclusion Criteria:
- Plasma Creatinine > 120 micromol/L
- Liverenzymes > 2 times the upper normal limit
- Gout
- Alcohol use > 2 units/day
- Illicit drug use
- Quit smoking less than 6 months ago
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
glucose tolerance
|
body weight
|
abdominal circumference
|
body composition measured by Dual Energy X-ray Absorptiometry
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hans de Boer, MD PhD, Rijnstate hospital, Arnhem, The Netherlands
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LTC-268-060504
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Diazoxide
-
Johns Hopkins UniversityNot yet recruitingMyocardial StunningUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedHypothalamic-pituitary Lesions | CraniopharyngiomasFrance
-
Virginia Commonwealth UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Johns Hopkins UniversityWithdrawn
-
Grill, Valdemar, M.D.Completed
-
University of DundeeJuvenile Diabetes Research FoundationCompleted
-
Essentialis, Inc.WithdrawnHypertriglyceridemia
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...SuspendedDiabetes Mellitus, Type 2 | Glucose, High Blood | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Active, not recruitingGlucose Metabolism Disorders | Type 2 Diabetes | Glucose, High BloodUnited States